Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 278

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 278
---
PIPE Financings

In February 2024, we issued
and sold an aggregate of 10,039 shares of Series A Preferred Stock, 6,127 Series A Warrants and 2,500 Preferred Warrants, at a price
of $1,000 per share of Series A Preferred Stock, for aggregate cash proceeds of approximately $8.0 million, plus additional cash proceeds
of up to $2.0 million if the Preferred Warrants are exercised.

The following table summarizes
the shares of our Series A Preferred Stock issued to our related parties:

| Purchasers(1)                   |     | Shares                 
 of Series A  Preferred 
 Stock                  |       |     | Total    
 Purchase 
 Price    |           |
|:--------------------------------|:----|:-----------------------|------:|:----|:---------|----------:|
| Daniel Corey(2)                 |     |                        |   150 |     | $        |   150,000 |
| Atwood-Edminster Trust dtd      
 4-2-2000 (3)                    |     |                        | 1,002 |     | $        | 1,002,000 |
| Chris Ehrlich(4)                |     |                        |   275 |     | $        |   275,000 |
| Phoenix Biotech Sponsor, LLC(5) |     |                        | 1,380 |     | $        | 1,380,000 |

| (1) | Additional details regarding                                                                                             
 these stockholders and their equity holdings are included in this prospectus under the section “Principal Stockholders.” |

| (2) | Daniel Corey served as                                                                                                             
 the Chief Technology Officer and a member of the board of directors from February 2024 to September 2024, and previously served as 
 Chief Executive Officer, Chief Scientific Officer, and a member of the board of directors of Legacy CERo until the closing of the  
 Business Combination in February 2024.                                                                                             |

| (3) | Brian G. Atwood served                                                                                                            
 as Chairman and Chief Executive Officer from February 2024 to September 2024, and previously served as Chairman of PBAX until the 
 closing of the Business Combination in February 2024 Mr. Atwood is a member of the board of directors and serves as a trustee of  
 Atwood-Edminster Trust dtd 4-2-2000.                                                                                              |

| (4) | Chris Ehrlich